Form 4: Kronos Bio Director's Options Cancelled Following Concentra Biosciences Acquisition

A recent SEC Form 4 filing reveals that Kronos Bio, Inc. Director Roger D. Dansey's stock options were cancelled as part of the company's acquisition by Concentra Biosciences, LLC, which included a tender offer of $0.57 per share cash plus a contingent value right.

Summary

• The filing reports the disposition of stock options held by Roger D. Dansey, a Director of Kronos Bio, Inc., due to the company's acquisition.
• This disposition occurred as a result of the Agreement and Plan of Merger, dated May 1, 2025, between Kronos Bio, Inc., Concentra Biosciences, LLC ("Parent"), and Concentra Merger Sub IV, Inc. ("Merger Sub").
• On June 18, 2025, Parent and Merger Sub completed a tender offer for all outstanding shares of Kronos Bio common stock at an offer price of $0.57 per share in cash (the "Cash Amount") plus one non-transferable contractual contingent value right (CVR).
• Following the tender offer, Merger Sub merged with and into Kronos Bio, making Kronos Bio a wholly owned subsidiary of Concentra Biosciences.
• Immediately prior to the merger's effective time, all outstanding stock options became fully vested and exercisable.
• Unexercised options were cancelled and converted into the right to receive cash equal to the product of (1) the excess of the Cash Amount ($0.57) over the option's exercise price and (2) the number of shares underlying the option, plus one CVR per underlying share.
• However, options with an exercise price equal to or greater than the Cash Amount ($0.57) were cancelled for no consideration.
• Roger D. Dansey disposed of 68,000 options with an exercise price of $1.28, 5,868 options with an exercise price of $1.48, and 34,000 options with an exercise price of $0.95. All these options had exercise prices greater than the $0.57 cash amount and were therefore cancelled for no consideration.

Sentiment

Score: 5

Explanation: Neutral. The document is a factual report of an insider transaction resulting from a completed merger. It reflects a standard outcome for options in an acquisition where the strike price is above the offer price, and does not convey positive or negative sentiment about the company's ongoing operations, as it is now a subsidiary.

Positives

• The merger completion indicates a successful acquisition for Kronos Bio shareholders who participated in the tender offer, receiving cash and CVRs.
• The options held by the director became fully vested prior to the merger, although they were cancelled for no consideration due to their exercise price being above the cash offer.

Negatives

• The reporting person's stock options (totaling 107,868 shares) were cancelled for no consideration because their exercise prices ($1.28, $1.48, $0.95) were all higher than the cash offer price of $0.57 per share.
• Kronos Bio, Inc. is no longer an independent publicly traded entity, becoming a wholly owned subsidiary, which means its stock will no longer trade on public exchanges.

Risks

• Holders of Contingent Value Rights (CVRs) face uncertainty regarding the value and realization of these rights, as their payout is contingent on future events or performance milestones not detailed in this filing.
• Shareholders who did not tender their shares in the offer would have had their shares converted into the merger consideration, potentially at a less favorable outcome if they held options with higher strike prices.

Future Outlook

The document indicates that Kronos Bio, Inc. has become a wholly owned subsidiary of Concentra Biosciences, LLC, implying its future operations and financial reporting will be integrated under the parent company. The future value for former shareholders who received CVRs is contingent on the terms of the CVR Agreement, which are not detailed in this filing.

Industry Context

This acquisition reflects a trend of consolidation within the biotechnology and pharmaceutical sectors, where larger entities or private equity firms acquire smaller, often clinical-stage, companies to expand pipelines or gain specific assets. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps, particularly for assets with uncertain future milestones or regulatory approvals.

Management Changes

Stakeholder Impact

• Shareholders (former): Those who tendered shares received $0.57 cash per share plus one CVR. Those who held options with strike prices above $0.57 received no cash for those options but did receive CVRs for the underlying shares.
• Employees: The document does not specify the impact on employees, but mergers often lead to organizational restructuring.
• Management (former): Directors like Roger D. Dansey are no longer subject to Section 16 reporting obligations for Kronos Bio, Inc. due to its change in status.

Next Steps

• Former Kronos Bio shareholders who received CVRs will await future announcements regarding the milestones or events that trigger payouts under the Contingent Value Rights Agreement.
• Kronos Bio, Inc. will operate as a wholly owned subsidiary of Concentra Biosciences, LLC, with its financial and operational reporting integrated into the parent company.

Key Dates

Keywords

Kronos Bio, KRON, Concentra Biosciences, Merger, Acquisition, Tender Offer, SEC Form 4, Insider Transaction, Stock Options, Contingent Value Rights, CVR, Biotechnology, Pharmaceuticals